Research / Stocks / IBIO IBIO Nasdaq CIK 0001420720
iBio, Inc. · Pharmaceutical Preparations
COVERAGE / STANDARD
Latest filing 4 · Aug 4, 2026
Research state The latest filing does not contain sufficient reviewed comparable structured data
Last SEC check Sep 13, 2026
Data basis Official SEC · no quote feed Component status Filing Evidence Research Current Official SEC filing history is available
Structured Financials Source Limited The latest filing model has no reviewed comparable financial mapping · NO_CURRENT_COMPARABLE_STATE
Filing Analysis Source Limited No filing analysis job is currently running · NO_CURRENT_COMPARABLE_STATE
Fundamental State Source Limited Fundamental State depends on validated comparable financial metrics · NO_CURRENT_COMPARABLE_STATE
RESEARCH SNAPSHOT iBio, Inc.'s latest supported as-filed period reports revenue of $0 . Every value below links to its SEC accession and metric lineage.
INSIDER STATE / 90D Recent disclosed activity
Open-market purchases 0
Sales 0
Distinct buyers 0
Repeat buyer NO Conservative Form 4 classification · not a sentiment label Flagship analysis / V3 What changed? The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Current 10-Q 0001104659-26-059416 3 governed changes · top 3 shown
01
HIGH IMPORTANCE Operating Income 67TH HISTORICAL PCTL · N=3
Operating income decreased 71.4% Operating income changed -71.4% from the comparable as-filed period.
Why this ranks here · [email protected] -$4.9M → -$8.4M Comparable → current
02
HIGH IMPORTANCE R And D 67TH HISTORICAL PCTL · N=3
Research & development increased 70.7% Research & development changed +70.7% from the comparable as-filed period.
Why this ranks here · [email protected] $1.9M → $3.3M Comparable → current
03
INFORMATIONAL IMPORTANCE Sbc 0TH HISTORICAL PCTL · N=3
Stock-based compensation increased 1.9% Stock-based compensation changed +1.9% from the comparable as-filed period.
Why this ranks here · [email protected] $370,000 → $377,000 Comparable → current
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
As-filed financials Financial trajectory Each point keeps the date investors could first observe it and its accession.
As filed Current normalized · later
Capex / revenue 32.00% +0.0% ↑ Capital expenditure $11,000 -97.9% ↓ Cash & equivalents $47.6M +0.0% ↑ Free-cash-flow proxy -$6.1M -5.9% ↓ Gross margin 90.94% -6.8% ↓ Interest expense $52,000 +52.9% ↑ Inventory $0 — Net income -$7.7M +14.0% ↑
ACTIVE TRACE Revenue IBIO · as filed with the SEC · reported-date aware
Capex / revenue Q1 / 2025-09-30 32.00% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Capital expenditure Q3 / 2026-03-31 $11,000 -97.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Cash & equivalents Q3 / 2026-03-31 $47.6M +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Free-cash-flow proxy Q3 / 2026-03-31 -$6.1M -5.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Gross margin FY / 2022-06-30 90.94% -6.8% sequential point Trace ↗ Evidence inspector
Loading lineage… × Interest expense Q3 / 2024-03-31 $52,000 +52.9% sequential point Trace ↗ Evidence inspector
Loading lineage… × Inventory FY / 2024-06-30 $0 Comparable n/a Trace ↗ Evidence inspector
Loading lineage… × Net income Q3 / 2026-03-31 -$7.7M +14.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating cash flow Q3 / 2026-03-31 -$6.1M -16.1% sequential point Trace ↗ Evidence inspector
Loading lineage… × Operating margin Q1 / 2025-09-30 -5951.00% +0.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Research & development Q3 / 2026-03-31 $3.3M -24.0% sequential point Trace ↗ Evidence inspector
Loading lineage… × Revenue Q3 / 2026-03-31 $0 Comparable n/a Trace ↗ Evidence inspector
Loading lineage… × Primary evidence Filing timeline Direct SEC links, filing dates, report periods, and amendment flags.
4 Aug 4, 2026 Period Jul 31, 2026 0001104659-26-090344SEC ↗ 8-K Aug 4, 2026 Period Jul 31, 2026 0001420720-26-000014SEC ↗ 8-K Jul 17, 2026 Period Jul 17, 2026 0001420720-26-000012SEC ↗ 8-K Jul 1, 2026 Period Jul 1, 2026 0001420720-26-000010SEC ↗ 4 May 19, 2026 Period May 18, 2026 0001104659-26-063503SEC ↗ 10-Q May 12, 2026 Period Mar 31, 2026 0001104659-26-059416SEC ↗ 8-K May 12, 2026 Period May 12, 2026 0001104659-26-059408SEC ↗ Form 4 Insider activity Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
“Insider purchase” rule Code P · non-derivative · acquired · direct ownership · positive price and shares · not amended
Inspectable by design
Every displayed number has a lineage. GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗